Graft Rejection in Endothelial Keratoplasty

  • Christine Shieh
  • Alan N. Carlson


Immune graft rejection is the primary cause of corneal graft failure and is an important emergency in patients who have undergone cornea transplantation. Corneal graft rejection is defined as an immunologic process to donor tissue in which there suddenly develops inflammation in the anterior segment and decompensated graft edema in a previously technically successful graft (Fig. 11.1) [1–3]. The criterion for a successful graft is one which has remained clear for at least 10–14 days, so as to distinguish from primary graft failure [4]. Rejection may be reversible or irreversible.


Rejection Rate Graft Rejection Rejection Episode Topical Steroid Penetrate Keratoplasty 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Koay PY, Lee WH, Figueiredo FC, et al. Opinions on risk factors and management of corneal graft rejection in the United Kingdom. Cornea. 2005;24:292–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Miedziak AI, Tambasco FP, Lucas-Glass TC, et al. Evaluation of triggers for corneal graft rejection. Ophthalmic Surg Lasers. 1999;30:133–9.PubMedGoogle Scholar
  3. 3.
    Polak FM. Corneal transplantations. Invest Ophthalmol Vis Sci. 1973;12:85–93.Google Scholar
  4. 4.
    Claerhout I, Beele H, Kestelyn P. Graft failure: I. Endothelial cell loss. Int Ophthalmol. 2008;28(3):165–73. Review.PubMedCrossRefGoogle Scholar
  5. 5.
    Price MO, Thompson Jr RW, Price Jr FW. Risk factors for various causes of failure in initial corneal grafts. Arch Ophthalmol. 2003;121(8):1087–92.PubMedCrossRefGoogle Scholar
  6. 6.
    Chen ES, Shamie N, Terry MA. Descemet-stripping endothelial keratoplasty: improvement in vision following replacement of a healthy endothelial graft. J Cataract Refract Surg. 2008;34:1044–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Terry MA. Precut tissue for Descemet stripping automated endothelial keratoplasty: complications are from technique, not tissue. Cornea. 2008;27:627–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Chen ES, Terry MA, Shamie N, et al. Precut tissue in Descemet’s stripping automated endothelial keratoplasty: donor characteristics and early postoperative complications. Ophthalmology. 2008;115:497–502.PubMedCrossRefGoogle Scholar
  9. 9.
    Terry MA, Chen ES, Shamie N, et al. Endothelial cell loss after Descemet’s stripping endothelial keratoplasty in a large prospective series. Ophthalmology. 2008;115:488–96.PubMedCrossRefGoogle Scholar
  10. 10.
    Terry MA, Shamie N, Chen ES, et al. Endothelial keratoplasty: a simplified technique to minimize graft dislocation, iatrogenic graft failure, and pupillary block. Ophthalmology. 2008;115:1179–86.PubMedCrossRefGoogle Scholar
  11. 11.
    Bierer BE, Mattila PS, Standaert RF, et al. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc Natl Acad Sci U S A. 1990;87:9231–5.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Binder PS, Gebhardt BM, Chandler JW, et al. Immunologic protection of rabbit corneal allografts with heterologous blocking antibody. Am J Ophthalmol. 1975;79:949–54.PubMedCrossRefGoogle Scholar
  13. 13.
    Böhnke M, Eggli P, Engelmann K. Transplantation of cultured adult human or porcine corneal endothelial cells onto human recipients in vitro. Part II: Evaluation in the scanning electron microscope. Cornea. 1999;18:207–13.PubMedCrossRefGoogle Scholar
  14. 14.
    Khodadoust AA, Karnema Y. Corneal grafts in the second eye. Cornea. 1984;3:17–20.PubMedCrossRefGoogle Scholar
  15. 15.
    Khodadoust AA, Silverstein AM. Transplantation and rejection of individual cell layers of the cornea. Invest Ophthalmol. 1969;8:180–95.PubMedGoogle Scholar
  16. 16.
    Klebe S, Sykes PJ, Coster DJ, et al. Prolongation of sheep corneal allograft survival by ex vivo transfer of the gene encoding interleukin-10. Transplantation. 2001;71:1214–20.PubMedCrossRefGoogle Scholar
  17. 17.
    Krachmer JH, Alldredge OC. Subepithelial infiltrates: a probable sign of corneal transplant rejection. Arch Ophthalmol. 1978;96:2234–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Küchle M, Cursiefen C, Nguyen NX, et al. Risk factors for corneal allograft rejection: intermediate results of a prospective normal-risk keratoplasty study. Graefes Arch Clin Exp Ophthalmol. 2002;240:580–4.PubMedCrossRefGoogle Scholar
  19. 19.
    Lam DS, Wong AK, Tham CC, Leung AT. The use of combined intravenous pulse methylprednisolone and oral cyclosporin A in the treatment of corneal graft rejection: a preliminary study. Eye. 1998;12:615–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Lange TM, Wood TO, McLaughlin BJ. Corneal endothelial cell transplantation using Descemets membrane as a carrier. J Cataract Refract Surg. 1993;19:232–5.PubMedCrossRefGoogle Scholar
  21. 21.
    Levenson JE, Brightbill FS. Endothelial rejection in human transplants. Arch Ophthalmol. 1973;89:489–92.PubMedCrossRefGoogle Scholar
  22. 22.
    Ma D, Mellon J, Niederkorn JY. Oral immunisation as a strategy for enhancing corneal allograft survival. Br J Ophthalmol. 1997;81:778–84.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Mac-Kay IR, Bignel JL, Smith PH, et al. Prevention of corneal graft failure with the immuno suppressive drug azothioprine. Lancet. 1967;7514:479.CrossRefGoogle Scholar
  24. 24.
    Maguire MG, Stark WJ, Gottsch JD, et al. Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Collaborative Corneal Transplantation Studies Research Group. Ophthalmology. 1994;101:1536–47.PubMedCrossRefGoogle Scholar
  25. 25.
    Mahlberg K, Uusitalo RJ, Oksala O. Prevention of high risk corneal graft rejection using cyclosporine A (CsA) incorporated into a collagen matrix. Ocul Immunol Inflamm. 1997;5:101–10.PubMedCrossRefGoogle Scholar
  26. 26.
    Mason CM, Sugar A, Meyer RF. Intrastromal crystalline deposits following corneal graft rejection. Cornea. 1984;3:89–94.PubMedCrossRefGoogle Scholar
  27. 27.
    Massry GG, Assil KK. Pilocarpine-associated allograft rejection in postkeratoplasty patients. Cornea. 1995;14:202–5.PubMedCrossRefGoogle Scholar
  28. 28.
    Maumenee AE. Clinical aspects of the corneal homograft reaction. Invest Ophthalmol. 1962;1:244–52.PubMedGoogle Scholar
  29. 29.
    Maumenee AE. The influence of donor recipient sensitization on corneal grafts. Am J Ophthalmol. 1951;34:142–52.PubMedCrossRefGoogle Scholar
  30. 30.
    Melles GR, Kamminga N. Techniques for posterior lamellar keratoplasty through a scleral incision. Ophthalmologe. 2003;100:689–95.PubMedCrossRefGoogle Scholar
  31. 31.
    Meyer PA, Watson PG, Franks W, et al. ‘Pulsed’ immunosuppressive therapy in the treatment of immunologically induced corneal and scleral disease. Eye. 1987;1:487–95.PubMedCrossRefGoogle Scholar
  32. 32.
    Mills RA, Jones DB, Winkler CR, et al. Topical FK-506 prevents experimental corneal allograft rejection. Cornea. 1995;14:157–60.PubMedCrossRefGoogle Scholar
  33. 33.
    Minamoto A, Sakata H, Okada K, et al. Suppression of corneal graft rejection by subconjunctival injection of FK- 506 in a rat model of penetrating keratoplasty. Jpn J Ophthalmol. 1995;39:12–9.PubMedGoogle Scholar
  34. 34.
    Moore TE, Aronson SB. Steroid therapy in penetrating keratoplasty. Trans Pac Coast Otoophthalmol Soc Annu Meet. 1967;51:29–40.PubMedGoogle Scholar
  35. 35.
    Morris RE, Wu J, Shorthouse R. A study of the contrasting effects of cyclosporine, FK 506, and rapamycin on the suppression of allograft rejection. Transplant Proc. 1990;22:1638–41.PubMedGoogle Scholar
  36. 36.
    Morris RJ, Kirkness CM. Emergency presentation of corneal graft patients. Eye. 1988;2(Pt 1):71–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Mayer DJ, Daar AS, Casey TA, Fabre JW. Localisation of HLA-A, B, C, and HLA-DR antigens in the human cornea: practical significance for grafting technique and HLA typing. Transplant Proc. 1983;15:126–9.Google Scholar
  38. 38.
    Treseler PA, Foulks GN, Sanfilippo F. The expression of HLA antigens by cells in the human cornea. Am J Opthalmol. 1984;98:763–72.CrossRefGoogle Scholar
  39. 39.
    Whitsett CF, Stulting RD. The distribution of HLA antigens on human corneal tissue. Invest Ophthalmol Vis Sci. 1984;25:519–24.PubMedGoogle Scholar
  40. 40.
    Dua HS, Shidham VB. Application of specific red blood cell adherence test to the human cornea and conjunctiva. Am J Ophthalmol. 1979;88:1067–71.PubMedCrossRefGoogle Scholar
  41. 41.
    Salisbury JD, Gebhardt BM. Blood group antigens on human corneal cells demonstrated by immunoperoxidase staining. Am J Ophthalmol. 1981;91:46–50.PubMedCrossRefGoogle Scholar
  42. 42.
    Dua HS, Azuara-Blanco A. Corneal allograft rejection: risk factors, diagnosis, prevention, and treatment. Indian J Ophthalmol. 1999;47:3–9.PubMedGoogle Scholar
  43. 43.
    Yamada J, Kurimoto I, Streilein JW. Role of CD4+ T cells in immunobiology of orthotopic corneal transplants in mice. Invest Ophthalmol Vis Sci. 1999;40(11):2614–21.PubMedGoogle Scholar
  44. 44.
    Barker CF, Billingham RE. Immunological privileged sites and tissues. In: Porter R, Knight J, editors. Corneal Graft Failure. CIBA Foundation Symposium 15 (New Series). Amsterdam: Elsevier Excerpta Medica North-Holland; 1973. p. 79–104.Google Scholar
  45. 45.
    Katami M. Corneal transplantation—immunologically privileged 174. Streilein JW. Immunological non-responsiveness and acquisition of tolerance in relation to immune privilege in the eye. Eye. 1995;9:236–40.Google Scholar
  46. 46.
    Streilein JW. Immunological non-responsiveness and acquisition of tolerance in relation to immune privilege in the eye. Eye. 1995;9:236–40.PubMedCrossRefGoogle Scholar
  47. 47.
    Niederkorn JY. Immunology and immunomodulation of corneal transplantation. Int Rev Immunol. 2002;21:173–96.PubMedCrossRefGoogle Scholar
  48. 48.
    Niederkorn JY. Effect of cytokine-induced migration of Langerhans cells on corneal allograft survival. Eye. 1995;9(Pt 2):215–8.PubMedCrossRefGoogle Scholar
  49. 49.
    Niederkorn JY, Peeler JS, Ross J, et al. The immunogenic privilege of corneal allografts. Reg Immunol. 1989;2:117–24.PubMedGoogle Scholar
  50. 50.
    Steinman RM, Nussenzweig MC. Dendritic cells: features and functions. Immunol Rev. 1980;53:127–47.PubMedCrossRefGoogle Scholar
  51. 51.
    Tommila P, Summanen P, Tervo T. Cortisone, heparin and argon laser in the treatment of corneal neovascularization. Acta Ophthalmol. 1987;182(Suppl):89–92.Google Scholar
  52. 52.
    Panda A, Vanathi M, Kumar A, Dash Y, Priya S. Corneal graft rejection. Surv Ophthalmol. 2007;52(4):375–96.PubMedCrossRefGoogle Scholar
  53. 53.
    Hegde S, Beauregard C, Mayhew E, Niederkorn JY. CD4(+) T-cell-mediated mechanisms of corneal allograft rejection: role of Fas-induced apoptosis. Transplantation. 2005;79(1):23–31 [PubMed].PubMedCrossRefGoogle Scholar
  54. 54.
    Claerhout I, Beele H, De Bacquer D, Kestelyn P. Factors influencing the decline in endothelial cell density after corneal allograft rejection. Invest Ophthalmol Vis Sci. 2003;44(11):4747–52.PubMedCrossRefGoogle Scholar
  55. 55.
    Monnereau C, Bruinsma M, Ham L, Baydoun L, Oellerich S, Melles GR. Endothelial cell changes as an indicator for upcoming allograft rejection following descemet membrane endothelial keratoplasty. Am J Ophthalmol. 2014;158(3):485–95.PubMedCrossRefGoogle Scholar
  56. 56.
    Melles GR, Eggink FA, Lander F, Pels E, Rietveld FJ, Beekhuis WH, Binder PS. A surgical technique for posterior lamellar keratoplasty. Cornea. 1998;17(6):618–26.PubMedCrossRefGoogle Scholar
  57. 57.
    Terry MA, Ousley PJ. Deep lamellar endothelial keratoplasty visual acuity, astigmatism, and endothelial survival in a large prospective series. Ophthalmology. 2005;112(9):1541–8.PubMedCrossRefGoogle Scholar
  58. 58.
    Melles GR, Wijdh RH, Nieuwendaal CP. A technique to excise the descemet membrane from a recipient cornea (descemetorhexis). Cornea. 2004;23(3):286–8.PubMedCrossRefGoogle Scholar
  59. 59.
    Price Jr FW, Price MO. Descemet’s stripping with endothelial keratoplasty in 50 eyes: a refractive neutral corneal transplant. J Refract Surg. 2005;21(4):339–45.PubMedGoogle Scholar
  60. 60.
    Price Jr FW, Price MO. Descemet’s stripping with endothelial keratoplasty in 200 eyes: Early challenges and techniques to enhance donor adherence. J Cataract Refract Surg. 2006;32(3):411–8.PubMedCrossRefGoogle Scholar
  61. 61.
    Figueiredo GS, Jones MN, Krishna Y, Figueiredo FC, Larkin DF, Kaye SB, National Health Service Blood and Transplant Ocular Tissue Advisory Group (OTAG); (OTAG Audit Study 17). Transplant rejection following endothelial keratoplasty and penetrating keratoplasty in the United Kingdom: incidence and survival. Am J Ophthalmol. 2015;160(3):416–21.PubMedCrossRefGoogle Scholar
  62. 62.
    Kosker M, Suri K, Duman F, Hammersmith KM, Nagra PK, Rapuano CJ. Long-term outcomes of penetrating keratoplasty and Descemet stripping endothelial keratoplasty for Fuchs endothelial dystrophy: fellow eye comparison. Cornea. 2013;32(8):1083–8.PubMedCrossRefGoogle Scholar
  63. 63.
    Allan BD, Terry MA, Price Jr FW, Price MO, Griffin NB, Claesson M. Corneal transplant rejection rate and severity after endothelial keratoplasty. Cornea. 2007;26(9):1039–42.PubMedCrossRefGoogle Scholar
  64. 64.
    Bahar I, Kaiserman I, McAllum P, Slomovic A, Rootman D. Comparison of posterior lamellar keratoplasty techniques to penetrating keratoplasty. Ophthalmology. 2008;115(9):1525–33. doi: 10.1016/j.ophtha.2008.02.010. Epub 2008 Apr 28.PubMedCrossRefGoogle Scholar
  65. 65.
    Anshu A, Price MO, Price Jr FW. Risk of corneal transplant rejection significantly reduced with Descemet’s membrane endothelial keratoplasty. Ophthalmology. 2012;119(3):536–40.PubMedCrossRefGoogle Scholar
  66. 66.
    Nanavaty MA, Shortt AJ. Endothelial keratoplasty versus penetrating keratoplasty for Fuchs endothelial dystrophy. Cochrane Database Syst Rev. 2011;(7).Google Scholar
  67. 67.
    Terry MA, Ousley PJ. Deep lamellar endothelial keratoplasty: Early complications and their management. Cornea. 2006;25(1):37–45.PubMedCrossRefGoogle Scholar
  68. 68.
    Price MO, Price Jr FW. Endothelial keratoplasty – a review. Clin Exp Ophthalmol. 2010;38(2):128–40.CrossRefGoogle Scholar
  69. 69.
    Price MO, Gorovoy M, Price Jr FW, Benetz BA, Menegay HJ, Lass JH. Descemet’s stripping automated endothelial keratoplasty: three-year graft and endothelial cell survival compared with penetrating keratoplasty. Ophthalmology. 2013;120(2):246–51.PubMedCrossRefGoogle Scholar
  70. 70.
    Mitry D, Bhogal M, Patel AK, Lee BS, Chai SM, Price MO, Price Jr FW, Jun AS, Aldave AJ, Mehta JS, Busin M, Allan BD. Descemet stripping automated endothelial keratoplasty after failed penetrating keratoplasty: survival, rejection risk, and visual outcome. JAMA Ophthalmol. 2014;132(6):742–9.PubMedCrossRefGoogle Scholar
  71. 71.
    Lee WB, Jacobs DS, Musch DC, Kaufman SC, Reinhart WJ, Shtein RM. Descemet’s stripping endothelial keratoplasty: safety and outcomes: a report by the American Academy of Ophthalmology. Ophthalmology. 2009;116(9):1818–30.PubMedCrossRefGoogle Scholar
  72. 72.
    Maier P, Reinhard T, Cursiefen C. Descemet stripping endothelial keratoplasty—rapid recovery of visual acuity. Dtsch Arztebl Int. 2013;110(21):365–71.PubMedPubMedCentralGoogle Scholar
  73. 73.
    Steven P, Hos D, Heindl L, Cursiefen C. Immune reactions after DMEK and DSAEK. Klin Monatsbl Augenheilkd. 2013;230:494–9.PubMedCrossRefGoogle Scholar
  74. 74.
    Chaurasia S, Price Jr FW, Gunderson L, Price MO. Descemet’s membrane endothelial keratoplasty: clinical results of single versus triple procedures (combined with cataract surgery). Ophthalmology. 2014;121(2):454–8.PubMedCrossRefGoogle Scholar
  75. 75.
    Hori J, Streilein JW. Survival in high risk eyes of epithelium-deprived orthotopic corneal allografts reconstituted in vitro with syngeneic epithelium. Invest Ophthalmol Vis Sci. 2003;44:658–64.PubMedCrossRefGoogle Scholar
  76. 76.
    Dunn SP, Gal RL, Kollman C, Raghinaru D, Dontchev M, Blanton CL, Holland EJ, Lass JH, Kenyon KR, Mannis MJ, Mian SI, Rapuano CJ, Stark WJ, Beck RW, Writing Committee for the Cornea Donor Study Research Group. Corneal graft rejection 10 years after penetrating keratoplasty in the cornea donor study. Cornea. 2014;33(10):1003–9.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Boisjoly HM, Roy R, Dube I, et al. HLA-A, B and DR matching in corneal transplantation. Ophthalmology. 1986;93:1290–7.PubMedCrossRefGoogle Scholar
  78. 78.
    Boisjoly HM, Roy R, Bernard P-M, et al. Association between corneal allograft reactions and HLA compatibility. Ophthalmology. 1990;97:1689–98.PubMedCrossRefGoogle Scholar
  79. 79.
    Volker-Dieben HJ, Kok-Van Alphen CC, Lansbergen Q, Persjin GG. Different influences on corneal graft survival in 539 transplants. Acta Ophthalmol. 1982;60:190–202.CrossRefGoogle Scholar
  80. 80.
    Allansmith MR, Drell DW, Kajiyama G. ABO blood groups and corneal transplantation. Am J Ophthalmol. 1975;79:493–501.PubMedCrossRefGoogle Scholar
  81. 81.
    The Collaborative Corneal Transplantation Studies Research Group. Designs and methods of the collaborative corneal transplantation studies. Cornea. 1993;12:93–103.CrossRefGoogle Scholar
  82. 82.
    Ehlers N, Ahrons S. Corneal transplantation and histocompatibility. Acta Ophthalmol. 1971;49:513–27.CrossRefGoogle Scholar
  83. 83.
    Stark WJ, Taylor HR, Bias WB, Maumenee AE. Histocompatibility (HLA) antigens and keratoplasty. Am J Ophthalmol. 1978;86:595–604.PubMedCrossRefGoogle Scholar
  84. 84.
    Vail A, Gore SM, Bradley BA, Eastly DL, Rogers CA, Armitage WL. Influence of donor and histocompatibility factors on corneal graft outcome. Transplantation. 1994;58:1210–7.PubMedGoogle Scholar
  85. 85.
    Batchelor JR, Casey TA, Werb A, Gibbs DC, Prasad SS, Lloyd DF, et al. HLA matching and corneal grafting. Lancet. 1976;i:551–4.CrossRefGoogle Scholar
  86. 86.
    Munkhbat B, Hagihara M, Sato T, Tsuchida F, Sato K, Shimazaki J, et al. Association between HLA-DPB1 matching and 1-year rejection-free graft survival in high-risk corneal transplantation. Transplantation. 1997;63:1011–6.PubMedCrossRefGoogle Scholar
  87. 87.
    Dua HS, Chan J, Gomes JAP, Azuara-Blanco A. Adverse effect of blood group ABO mismatching on corneal epithelial cells. Lancet. 1998;352:1677–8.PubMedCrossRefGoogle Scholar
  88. 88.
    Volker-Dieben HJ, D’ Amaro J, Kok-Van Alphen CC. Hierarchy of prognostic factors for corneal allograft survival. Aust N Z J Ophthalmol. 1987;15:11–8.PubMedCrossRefGoogle Scholar
  89. 89.
    Boisjoly HM, Bernanrd P-M, Dube I, Laughera P-A, Bazin R, Bermier J. Effect of factors unrelated to tissue matching on corneal transplant endothelial rejection. Am J Ophthalmol. 1989;107:647–54.PubMedCrossRefGoogle Scholar
  90. 90.
    Jonas JB, Rank RM, Budde WM. Immunologic graft reactions after allogenic penetrating keratoplasty. Am J Ophthalmol. 2002;133(4):437–43.PubMedCrossRefGoogle Scholar
  91. 91.
    Price MO, Price Jr FW, Kruse FE, Bachmann BO, Tourtas T. Randomized comparison of topical prednisolone acetate 1% versus fluorometholone 0.1% in the first year after descemet membrane endothelial keratoplasty. Cornea. 2014;33(9):880–6.PubMedCrossRefGoogle Scholar
  92. 92.
    Price MO, Jordan CS, Moore G, Price Jr FW. Graft rejection episodes after Descemet stripping with endothelial keratoplasty: part two: the statistical analysis of probability and risk factors. Br J Ophthalmol. 2009;93(3):391–5.PubMedCrossRefGoogle Scholar
  93. 93.
    Musch DC, Meyer RF. Risk of endothelial rejection after bilateral penetrating keratoplasty. Ophthalmology. 1989;96:1139–43.PubMedCrossRefGoogle Scholar
  94. 94.
    Sanfilippo F, MacQueen JM, Vaughn WK, Foulks GN. Reduced graft rejection with good HLA-A and B matching in high-risk corneal transplantation. N Engl J Med. 1986;315:29–35.PubMedCrossRefGoogle Scholar
  95. 95.
    Kusumesh R, Vanathi M. Graft rejection in pediatric penetrating keratoplasty: clinical features and outcomes. Oman J Ophthalmol. 2015;8(1):33–7.PubMedPubMedCentralCrossRefGoogle Scholar
  96. 96.
    Solomon A, Frucht-Pery J. Bilateral simultaneous corneal graft rejection after influenza vaccination. Am J Ophthalmol. 1996;121:708–9.PubMedCrossRefGoogle Scholar
  97. 97.
    Hill JC. Immunosuppression in corneal transplantation. Eye. 1995;9:247–53.PubMedCrossRefGoogle Scholar
  98. 98.
    The Collaborative Corneal Transplantation Studies (CCTS) Research Group. Effectiveness of histocompatibility matching in high-risk corneal transplantation. Arch Ophthalmol. 1992;110:1392–3.CrossRefGoogle Scholar
  99. 99.
    Yin D, Huang A, Warrow D, Ritterband DC, Seedor JA, McCormick SA, Milman T. Detection of herpes simplex virus type 1 in failed descemet stripping automated endothelial keratoplasty grafts. Cornea. 2013;32(9):1189–92.PubMedCrossRefGoogle Scholar
  100. 100.
    Vail A, Gore SM, Bradley BA, Eastly DL, Rogers CA, Armitage WL. Clinical and surgical factors influencing corneal graft survival, visual acuity, and astigmatism. Ophthalmology. 1996;103:41–9.PubMedCrossRefGoogle Scholar
  101. 101.
    Moll AC, Van Rij G, Beekhuis G, Reneradel De Lavalette JHC, Hermans J, Pels E, et al. Effect of donor cornea preservation in tissue culture and in Mc Carey-Kaufmann medium on corneal graft rejection and visual acuity. Doc Ophthalmol. 1991;78:273–8.PubMedCrossRefGoogle Scholar
  102. 102.
    Gillette TE, Chandler JW, Greiner JV. Langerhans cells of the ocular surface. Ophthalmology. 1982;89:700–11.PubMedCrossRefGoogle Scholar
  103. 103.
    Gong N, Pleyer U, Yang J, et al. Influence of local and systemic CTLA4Ig gene transfer on corneal allograft survival. J Gene Med. 2006;8:459–67.PubMedCrossRefGoogle Scholar
  104. 104.
    Hudde T, Minassian DC, Larkin DF. Randomised controlled trial of corticosteroid regimens in endothelial corneal allograft rejection. Br J Ophthalmol. 1999;83:1348–52.PubMedPubMedCentralCrossRefGoogle Scholar
  105. 105.
    Holland EJ, Olsen TW. Immunosuppression in high risk patients. In: BrightBill FS, editor. Corneal surgery – theory, technique and tissue. 2nd ed. St Louis: CV Mosby Company; 1997. p. 260–8.Google Scholar
  106. 106.
    Hill JC. The use of cyclosporine in high-risk keratoplasty. Am J Ophthalmol. 1989;107:506–10.PubMedCrossRefGoogle Scholar
  107. 107.
    Hill JC. Systemic cyclosporine in high-risk keratoplasty: short versus long term therapy. Ophthalmology. 1994;101:128–33.PubMedCrossRefGoogle Scholar
  108. 108.
    Miller K, Huber C, Niederwieser D, Gottinger W. Successful engraftment of high risk corneal allografts with short term immunosuppression with cyclosporine. Transplantation. 1988;45:651–3.PubMedCrossRefGoogle Scholar
  109. 109.
    Banerjee S, Dick AD. Recent developments in the pharmacological treatment and prevention of corneal graft rejection. Expert Opin Investig Drugs. 2003;12:29–37.PubMedCrossRefGoogle Scholar
  110. 110.
    Belin MW, Bouchard CS, Phillips TM. Update on topical cyclosporin A: background, immunology, and pharmacology. Cornea. 1990;9:184–95.PubMedCrossRefGoogle Scholar
  111. 111.
    Belin MW, Bouchard CS, Frantz S, Chmielinska J. Topical cyclosporine in high-risk corneal transplants. Ophthalmology. 1989;96:1144–50.PubMedCrossRefGoogle Scholar
  112. 112.
    Price M, Price F. Efficacy of topical cyclosporine 0.05% for prevention of cornea transplant rejection episodes. Ophthalmology. 2006;113:1785–90.PubMedCrossRefGoogle Scholar
  113. 113.
    Gregory CR, Hietala SK, Pedersen NC, Gregory TA, Floyd-Hawkins KA, Patz JD. Cyclosporine pharmacokinetics in cats following topical ocular administration. Transplantation. 1989;47:516–9.PubMedCrossRefGoogle Scholar
  114. 114.
    Ishioka M, Ohno S, Nakamura S, et al. FK506 treatment of noninfectious uveitis. Am J Ophthalmol. 1994;118:723–9. 35.PubMedCrossRefGoogle Scholar
  115. 115.
    Mochizuki M, Masuda K, Sakane T, et al. A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol. 1993;115:763–9.PubMedCrossRefGoogle Scholar
  116. 116.
    Hogan AC, McAvoy CE, Dick AD, et al. Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology. 2007;114:1000–6.PubMedCrossRefGoogle Scholar
  117. 117.
    Figueroa MS, Ciancas E, Orte L. Long-term follow-up of tacrolimus treatment in immune posterior uveitis. Eur J Ophthalmol. 2007;17:69–74.PubMedGoogle Scholar
  118. 118.
    Reis A, Reinhard T, Sundmacher R, et al. A comparative investigation of FK506 and cyclosporine A in murine corneal transplantation. Graefes Arch Clin Exp Ophthalmol. 1998;236:785–9.PubMedCrossRefGoogle Scholar
  119. 119.
    Sloper CM, Powell RJ, Dua H. Tacrolimus (FK506) in the management of high-risk corneal and limbal grafts. Ophthalmology. 2001;108:1838–44.PubMedCrossRefGoogle Scholar
  120. 120.
    Dhaliwal JS, et al. Long term use of topical tacrolimus (FK506) in high risk keratoplasty. Cornea. 2008;27(4):488–93.PubMedCrossRefGoogle Scholar
  121. 121.
    Hikita N, Lopez JS, Chan CC, Mochizuki M, Nussenblatt RB, de Smet MD. Use of topical FK506 in a corneal graft rejection model in Lewis rats. Invest Ophthalmol Vis Sci. 1997;38(5):901–9.PubMedGoogle Scholar
  122. 122.
    Ma D, Mellon H, Niederkorn JY. Oral immunization as a strategy for enhancing corneal allograft survival. Br J Ophthalmol.Google Scholar
  123. 123.
    Ma D, Mellon J, Niederkorn JY. Conditions affecting enhanced corneal allograft survival by oral immunization. Invest Ophthalmol Vis Sci. 1998;39:1835–46.PubMedGoogle Scholar
  124. 124.
    Ma D, Li X-Y, Mellon J, Niederkorn JY. Immunologic phenotype of hosts orally immunized with corneal alloantigens. Invest Ophthalmol Vis Sci. 1998;39:744–53.PubMedGoogle Scholar
  125. 125.
    He Y-G, Mellon J, Niederkorn JY. The effect of oral immunization on corneal allograft survival. Transplantation. 1996;61:920–6.PubMedCrossRefGoogle Scholar
  126. 126.
    He Y-G, Niederkorn JY. Depletion of donor-derived Langerhans cells promotes corneal allograft survival. Cornea. 1996;15:82–9.PubMedCrossRefGoogle Scholar
  127. 127.
    Yamagami S, Tsuru T, Isobe M, Osata H, Suzuki J-I. The role of cell adhesion molecules in allograft rejection after penetrating keratoplasty in mice. Clinical and immunohistochemical study. Graefes Arch Clin Exp Ophthalmol. 1996;234:382–7.PubMedCrossRefGoogle Scholar
  128. 128.
    Pleyer U, Milani JK, Ruckert D, Rieck P, Mondino BJ. Determination of serum tumor necrosis factor alpha in corneal allografts. Ocul Immunol Inflamm. 1997;5:149–55.PubMedCrossRefGoogle Scholar
  129. 129.
    Chan AS, Mehta JS, Al Jajeh I, Iqbal J, Anshu A, Tan DT. Histological features of Cytomegalovirus-related corneal graft infections, its associated features and clinical significance. Br J Ophthalmol. 2016;100(5):601–6.Google Scholar
  130. 130.
    Cheng YY, Schouten JS, Tahzib NG et al. Efficacy and safety of femtosecond laser-assisted corneal endothelial keratoplasty: a randomized multicenter clinical trial. Transplantation. 2009;88(11):1294–1302.Google Scholar
  131. 131.
    Coster DJ, Lowe MT, Keane MC, Williams KA. A comparison of lamellar and penetrating keratoplasty outcomes: a registry study. Ophthalmology. 2014;121(5):979–87.Google Scholar
  132. 132.
    Keane MC, Galettis RA, Mills RA, Coster DJ, Williams KA. A comparison of endothelial and penetrating keratoplasty outcomes following failed penetrating keratoplasty: a registry study. Br J Ophthalmol. 2016.Google Scholar
  133. 133.
    Ramamurthy S, Reddy JC, Vaddavalli PK, Ali MH, Garg P. Outcomes of Repeat Keratoplasty for Failed Therapeutic Keratoplasty. Am J Ophthalmol. 2016;162:83–8.e82.Google Scholar
  134. 134.
    Gundlach E, Maier AK, Riechardt AI, Brockmann T, Bertelmann E, Joussen A, et al. Descemet Membrane Endothelial Keratoplasty as a Secondary Approach After Failure of Penetrating Keratoplasty. Experimental and clinical transplantation: official journal of the Middle East Society for Organ Transplantation. 2015;13(4):350–4.Google Scholar
  135. 135.
    Guerra FP, Anshu A, Price MO, Price FW. Endothelial keratoplasty: fellow eyes comparison of Descemet stripping automated endothelial keratoplasty and Descemet membrane endothelial keratoplasty. Cornea. 2011;30(12):1382–6.Google Scholar
  136. 136.
    Price MO, Feng MT, McKee Y, Price FW, Jr. Repeat Descemet Membrane Endothelial Keratoplasty: Secondary Grafts with Early Intervention Are Comparable with Fellow-Eye Primary Grafts. Ophthalmology. 2015;122(8):1639–44.Google Scholar
  137. 137.
    Price MO, Scanameo A, Feng MT, Price FW, Jr. Descemet’s Membrane Endothelial Keratoplasty: Risk of Immunologic Rejection Episodes after Discontinuing Topical Corticosteroids. Ophthalmology. 2016.Google Scholar
  138. 138.
    Anshu A, Price MO, Price FW. Descemet’s stripping endothelial keratoplasty: long-term graft survival and risk factors for failure in eyes with preexisting glaucoma. Ophthalmology. 2012;119(10):1982–7.Google Scholar
  139. 139.
    Jampel HD, Solus JF, Tracey PA, Gilbert DL, Loyd TL, Jefferys JL, et al. Outcomes and bleb-related complications of trabeculectomy. Ophthalmology. 2012;119(4):712–22.Google Scholar
  140. 140.
    Vanathi M, Panda A, Vengayil S, Chaudhuri Z, Dada T. Pediatric keratoplasty. Survey of Ophthalmology. 2009;54(2):245–71.Google Scholar
  141. 141.
    Madi S, Santorum P, Busin M. Descemet stripping automated endothelial keratoplasty in pediatric age group. Saudi Journal of Ophthalmology: Official Journal of the Saudi Ophthalmological Society. 2012;26(3):309–13.Google Scholar
  142. 142.
    Hill JC, Maske R, Watson P. Corticosteroids in corneal graft rejection. Oral versus single pulse therapy. Ophthalmology. 1991;98(3):329–33.Google Scholar
  143. 143.
    Costa DC, de Castro RS, Kara-Jose N. Case-control study of subconjunctival triamcinolone acetonide injection vs intravenous methylprednisolone pulse in the treatment of endothelial corneal allograft rejection. Eye (Lond) 2009;23:708–14.Google Scholar
  144. 144.
    Abudou M, Wu T, Evans JR, Chen X. Immunosuppressants for the prophylaxis of corneal graft rejection after penetrating keratoplasty. The Cochrane database of systematic reviews. 2015;8:Cd007603.Google Scholar
  145. 145.
    Kharod-Dholakia B, Randleman JB, Bromley JG, Stulting RD. Prevention and treatment of corneal graft rejection: current practice patterns of the Cornea Society (2011). Cornea. 2015;34(6):609–14.Google Scholar
  146. 146.
    Cosar CB, Laibson PR, Cohen EJ, Rapuano CJ. Topical cyclosporine in pediatric keratoplasty. Eye & Contact Lens. 2003;29(2):103–7.Google Scholar
  147. 147.
    Unal M, Yucel I. Evaluation of topical ciclosporin 0.05% for prevention of rejection in high-risk corneal grafts. Br J Ophthalmol. 2008;92(10):1411–14.Google Scholar
  148. 148.
    Javadi MA, Feizi S, Karbasian A, Rastegarpour A. Efficacy of topical ciclosporin A for treatment and prevention of graft rejection in corneal grafts with previous rejection episodes. Br J Ophthalmol. 2010;94(11):1464–67.Google Scholar
  149. 149.
    Zhang YQ, Chen JQ, Zhou LH, Shi WY, Wang LY, Wang YQ. The randomised double blindness, multi-center clinical trial for CsA on rejection following penetrating keratoplasty. Chinese Ophthalmic Research. 2009;27.Google Scholar
  150. 150.
    Price MO, Feng MT, Scanameo A, Price FW, Jr. Loteprednol Etabonate 0.5% Gel Vs. Prednisolone Acetate 1% Solution After Descemet Membrane Endothelial Keratoplasty: Prospective Randomized Trial. Cornea. 2015;34(8):853–8.Google Scholar

Copyright information

© Springer India 2016

Authors and Affiliations

  1. 1.DurhamUK
  2. 2.Department of Corneal and Refractive SurgeryDuke Eye CenterDurhamUK

Personalised recommendations